Investigating the Effect of Atorvastatin on the Cisplatin-Induced Nephrotoxicity

References

• 1.
  Rozencweig M, von Hoff DD, Slavik M, Muggia FM. Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med. 1977;86(6):803-12. [PubMed ID:326117]. https://doi.org/10.7326/0003-4819-86-6-803.
• 2.
  Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490-518. [PubMed ID:22069563]. [PubMed Central ID:PMC3153174]. https://doi.org/10.3390/toxins2112490.
• 3.
  Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902. [PubMed ID:25020203]. [PubMed Central ID:PMC4096506]. https://doi.org/10.1371/journal.pone.0101902.
• 4.
  Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826. [PubMed ID:25165721]. [PubMed Central ID:PMC4140112]. https://doi.org/10.1155/2014/967826.
• 5.
  Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34(10):1522-34. [PubMed ID:9893623]. https://doi.org/10.1016/s0959-8049(98)00224-x.
• 6.
  Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol. 2000;278(5):F726-36. [PubMed ID:10807584]. https://doi.org/10.1152/ajprenal.2000.278.5.F726.
• 7.
  Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med. 1978;65(2):307-14. [PubMed ID:99034]. https://doi.org/10.1016/0002-9343(78)90825-2.
• 8.
  Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293-308. [PubMed ID:9225947]. https://doi.org/10.1007/s002800050661.
• 9.
  Reece PA, Stafford I, Russell J, Khan M, Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5(2):304-9. [PubMed ID:3806171]. https://doi.org/10.1200/JCO.1987.5.2.304.
• 10.
  Caglar K, Kinalp C, Arpaci F, Turan M, Saglam K, Ozturk B, et al. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant. 2002;17(11):1931-5. [PubMed ID:12401849]. https://doi.org/10.1093/ndt/17.11.1931.
• 11.
  Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15-25. [PubMed ID:28382507]. https://doi.org/10.1007/s40620-017-0392-z.
• 12.
  Miyoshi T, Uoi M, Omura F, Tsumagari K, Maesaki S, Yokota C. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study. Oncology. 2021;99(2):105-13. [PubMed ID:32966986]. https://doi.org/10.1159/000510384.
• 13.
  Peres LA, da Cunha AD. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol. 2013;35(4):332-40. [PubMed ID:24402113]. https://doi.org/10.5935/0101-2800.20130052.
• 14.
  dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol. 2012;86(8):1233-50. [PubMed ID:22382776]. https://doi.org/10.1007/s00204-012-0821-7.
• 15.
  Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994-1007. [PubMed ID:18272962]. https://doi.org/10.1038/sj.ki.5002786.
• 16.
  Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, et al. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther. 2007;322(1):8-15. [PubMed ID:17400889]. https://doi.org/10.1124/jpet.107.119792.
• 17.
  Aydinoz S, Uzun G, Cermik H, Atasoyu EM, Yildiz S, Karagoz B, et al. Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity. Ren Fail. 2007;29(3):257-63. [PubMed ID:17497437]. https://doi.org/10.1080/08860220601166487.
• 18.
  Ozbek E, Cekmen M, Ilbey YO, Simsek A, Polat EC, Somay A. Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways. Ren Fail. 2009;31(5):382-92. [PubMed ID:19839839]. https://doi.org/10.1080/08860220902835863.
• 19.
  Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000;58(4):1420-30. [PubMed ID:11012877]. https://doi.org/10.1046/j.1523-1755.2000.00304.x.
• 20.
  Khoshnoud MJ, Moghbel BNA, Niknahad H, Geramizadeh B. Effect of Simvastatin on Cisplatin-induced Nephrotoxicity in Male Rats: Prevention of cisplatin-induced nephrotoxicity. Iran J Pharm Sci. 2011;7(3):165-73.
• 21.
  Abady AH, Abu-Raghif AR, Qasim BJ. Effects of Atorvastatin against Cisplatin Induced Nephrotoxicity in Rabbits. Int J. 2015;3(10):879-85.
• 22.
  Fujieda M, Morita T, Naruse K, Hayashi Y, Ishihara M, Yokoyama T, et al. Effect of pravastatin on cisplatin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2011;30(7):603-15. [PubMed ID:20650967]. https://doi.org/10.1177/0960327110376551.
• 23.
  Iseri S, Ercan F, Gedik N, Yuksel M, Alican I. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology. 2007;230(2-3):256-64. [PubMed ID:17196726]. https://doi.org/10.1016/j.tox.2006.11.073.
• 24.
  An Y, Xin H, Yan W, Zhou X. Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice. Exp Toxicol Pathol. 2011;63(3):215-9. [PubMed ID:20060696]. https://doi.org/10.1016/j.etp.2009.12.002.
• 25.
  Boorla SK, Panchagiri S, Shastrala KK, Bonagiri R, Vangala M. Evaluation of role of atorvastatin in cisplatin induced nephrotoxicity in wistar rats. Global J Pharmacol. 2014;8(2):279-83.
• 26.
  Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-9. [PubMed ID:22762315]. [PubMed Central ID:PMC4398023]. https://doi.org/10.1056/NEJMoa1114248.
• 27.
  Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110(6):835-42. [PubMed ID:12235115]. [PubMed Central ID:PMC151130]. https://doi.org/10.1172/JCI15606.
• 28.
  Kelly KJ, Meehan SM, Colvin RB, Williams WW, Bonventre JV. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int. 1999;56(3):922-31. [PubMed ID:10469360]. https://doi.org/10.1046/j.1523-1755.1999.00629.x.
• 29.
  Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 2005;289(1):F166-74. [PubMed ID:15701814]. https://doi.org/10.1152/ajprenal.00401.2004.
• 30.
  Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol. 2004;286(3):F572-80. [PubMed ID:14612380]. https://doi.org/10.1152/ajprenal.00190.2003.
• 31.
  Maheshwari RA, Sailor GU, Patel L, Balaraman R. Amelioration of cisplatin-induced nephrotoxicity by statins. Indian J Pharmacol. 2013;45(4):354-8. [PubMed ID:24014910]. [PubMed Central ID:PMC3757603]. https://doi.org/10.4103/0253-7613.115016.
• 32.
  Rasha ME, Dalia SO, Dina MF. Cisplatin-Induced nephrotoxicity in rats: modulatory role of simvastatin and rosuvastatin against apoptosis and inflammation. J Appl Pharm Sci. 2018;8(4):043-50.